Skip to main content

Compare Stocks

Date Range: 

 Bicycle TherapeuticsVBI VaccinesBELLUS HealthXenon PharmaceuticalsCalliditas Therapeutics AB (publ)
SymbolNASDAQ:BCYCNASDAQ:VBIVOTCMKTS:BLUSFNASDAQ:XENENASDAQ:CALT
Price Information
Current Price$31.18$2.92$3.64$17.34$27.71
52 Week RangeBuyBuyN/ABuyBuy
MarketRank™
Overall Score1.31.50.51.61.3
Analysis Score3.53.60.03.53.5
Community Score2.43.22.52.72.6
Dividend Score0.00.00.00.00.0
Ownership Score0.80.80.01.70.0
Earnings & Valuation Score0.00.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyN/ABuyBuy
Consensus Price Target$43.00$7.00N/A$25.25$40.80
% Upside from Price Target37.91% upside139.73% upsideN/A45.62% upside47.24% upside
Trade Information
Market Cap$749.19 million$742.25 million$579.19 million$710.37 million$691.95 million
Beta-0.212.141.551.2N/A
Average Volume160,8485,867,60839,610176,04839,291
Sales & Book Value
Annual Revenue$13.80 million$2.22 million$30,000.00$6.83 million$19.56 million
Price / Sales54.29334.3519,306.20104.0135.38
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.27 per share$0.50 per share$0.25 per share$2.99 per shareN/A
Price / Book5.925.8414.565.80∞
Profitability
Net Income$-30,610,000.00$-54,810,000.00$-7,010,000.00$-41,600,000.00$-3,450,000.00
EPS($2.77)($0.46)N/A($1.54)($0.19)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/A∞N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-321.26%-2,837.73%-49,910.34%-102.25%N/A
Return on Equity (ROE)-42.73%-36.69%-48.37%-21.76%-26.80%
Return on Assets (ROA)-28.77%-28.29%-45.25%-16.08%-25.38%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.13%0.10%N/AN/AN/A
Current Ratio9.63%9.06%13.87%9.83%23.46%
Quick Ratio9.63%8.95%13.87%9.83%23.46%
Ownership Information
Institutional Ownership Percentage42.68%52.13%N/A79.90%11.85%
Insider Ownership Percentage26.30%10.50%24.17%8.35%N/A
Miscellaneous
Employees871271012334
Shares Outstanding24.03 million254.20 million159.12 million40.97 million24.97 million
Next Earnings Date8/4/2021 (Estimated)7/30/2021 (Estimated)N/A8/5/2021 (Estimated)5/18/2021 (Confirmed)
OptionableNot OptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
Calliditas Therapeutics AB (publ) (CALT) to Release Quarterly Earnings on TuesdayCalliditas Therapeutics AB (publ) (CALT) to Release Quarterly Earnings on Tuesday
americanbankingnews.com - May 15 at 9:14 AM
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021
finance.yahoo.com - May 14 at 12:53 PM
Genkyotex Provides Business Update and Reports Cash Position at March 31, 2021Genkyotex Provides Business Update and Reports Cash Position at March 31, 2021
businesswire.com - May 13 at 9:35 PM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives Average Rating of "Buy" from BrokeragesCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives Average Rating of "Buy" from Brokerages
americanbankingnews.com - May 12 at 6:12 AM
Calliditas promotes Andrew Udell to President, North AmericaCalliditas promotes Andrew Udell to President, North America
finance.yahoo.com - May 3 at 12:01 PM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading VolumeCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading Volume
americanbankingnews.com - April 30 at 11:41 AM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $28.76Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $28.76
americanbankingnews.com - April 28 at 11:05 AM
FDA grants priority review for Nefecon, for patients with IgA nephropathyFDA grants priority review for Nefecon, for patients with IgA nephropathy
finance.yahoo.com - April 28 at 4:28 AM
Calliditas Therapeutics 2020 Annual Report PublishedCalliditas Therapeutics' 2020 Annual Report Published
finance.yahoo.com - April 27 at 12:30 PM
Calliditas Therapeutics AB: Change in financial calendarCalliditas Therapeutics AB: Change in financial calendar
finance.yahoo.com - April 27 at 12:30 PM
EMA grants accelerated assessment procedure for Calliditas’ Nefecon to treat IgA nephropathyEMA grants accelerated assessment procedure for Calliditas’ Nefecon to treat IgA nephropathy
pharmabiz.com - April 24 at 11:04 AM
EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA NephropathyEMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy
finance.yahoo.com - April 23 at 7:33 AM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $26.02Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $26.02
americanbankingnews.com - April 21 at 1:38 PM
Calliditas Therapeutics Files US Application For Nefecon In Kidney DiseaseCalliditas Therapeutics Files US Application For Nefecon In Kidney Disease
finance.yahoo.com - March 15 at 2:40 PM
Agenda for Calliditas virtual R&D Day on January 20, 2021Agenda for Calliditas virtual R&D Day on January 20, 2021
prnewswire.com - January 15 at 4:35 AM
DateCompanyBrokerageAction
5/13/2021Bicycle TherapeuticsHC WainwrightBoost Price Target
5/11/2021Bicycle TherapeuticsOppenheimerBoost Price Target
5/7/2021Bicycle TherapeuticsPiper SandlerBoost Price Target
4/26/2021Bicycle TherapeuticsJMP SecuritiesInitiated Coverage
1/20/2021Bicycle TherapeuticsCantor FitzgeraldBoost Price Target
9/10/2020Bicycle TherapeuticsCanaccord GenuityBoost Price Target
11/14/2019Bicycle TherapeuticsRoth CapitalInitiated Coverage
9/11/2019Bicycle TherapeuticsThe Goldman Sachs GroupUpgrade
6/17/2019Bicycle TherapeuticsJefferies Financial GroupInitiated Coverage
8/26/2020VBI VaccinesRaymond JamesUpgrade
6/29/2020VBI VaccinesBMO Capital MarketsReiterated Rating
5/13/2021Xenon PharmaceuticalsSVB LeerinkReiterated Rating
3/8/2021Xenon PharmaceuticalsNeedham & Company LLCBoost Price Target
3/5/2021Xenon PharmaceuticalsWilliam BlairReiterated Rating
8/13/2020Xenon PharmaceuticalsBloom BurtonReiterated Rating
3/24/2020Xenon PharmaceuticalsWedbushInitiated Coverage
9/20/2019Xenon PharmaceuticalsGuggenheimInitiated Coverage
3/29/2019Xenon PharmaceuticalsStifel NicolausReiterated Rating
8/18/2020Calliditas Therapeutics AB (publ)Ci CapitalReiterated Rating
7/1/2020Calliditas Therapeutics AB (publ)CitigroupInitiated Coverage
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.